Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Carna Biosciences's share price for the quarter that ended in Dec. 2025 was 円356. Carna Biosciences's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 19.1 Mil. Therefore, Carna Biosciences's market cap for the quarter that ended in Dec. 2025 was 円6,813.5 Mil.
Carna Biosciences's quarterly market cap
increased
from Mar. 2025 (円5,537.8 Mil) to Jun. 2025 (円6,629.1 Mil) and
increased
from Jun. 2025 (円6,629.1 Mil) to Dec. 2025 (円6,813.5 Mil).
Carna Biosciences's annual market cap
declined
from Dec. 2023 (円8,949.7 Mil) to Dec. 2024 (円5,728.8 Mil) but then
increased
from Dec. 2024 (円5,728.8 Mil) to Dec. 2025 (円6,813.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Carna Biosciences's Enterprise Value for Today is 円7,239.7 Mil.
Carna Biosciences (TSE:4572) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Carna Biosciences Market Cap Related Terms
Carna Biosciences Market Cap Historical Data
* Premium members only.
The historical data trend for Carna Biosciences's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4572 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Carna Biosciences's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Carna Biosciences Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Carna Biosciences's Market Cap distribution charts can be found below:
* The bar in red indicates where Carna Biosciences's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Carna Biosciences's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Carna Biosciences (TSE:4572) has a Market Cap of 円6,523.1 Mil as of Jul. 01, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Carna Biosciences and its competitors. According to the industry distribution chart, Carna Biosciences ranks #944 out of 1427 companies in the Biotechnology industry, placing it in the top 66.2%.
Is Carna Biosciences' Market Cap too high?
Carna Biosciences' current Market Cap is 円6,523.1 Mil. Based on the distribution chart, Carna Biosciences ranks #944 out of 1427 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Carna Biosciences has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Carna Biosciences ranks #944 out of 1427 companies for Market Cap. This places Carna Biosciences in the lower half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Carna Biosciences and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Carna Biosciences's current Market Cap is 円6,523.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円175.07, compared to a current price of 円340.00 — trading 94.2% above its estimated fair value. The current Market Cap is 円6,523.1 Mil. Carna Biosciences' overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Market Cap is 円6,523.1 Mil as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Carna Biosciences (TSE:4572) Overvalued in 2026?
Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued.
The current stock price of 円340.00 is trading 94.2% above its estimated GF Value™ of 円175.07.
GuruFocus considers Carna Biosciences to be Significantly Overvalued.
Key valuation signals for TSE:4572:
Market Cap: 円6,523.1 Mil
GF Value™: 円175.07 vs. price of 円340.00 (94.2% above fair value)
No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
24GF Score
Get the complete analysis for TSE:4572
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4572 has been successfully added to your 
